Clinical Guidelines
Heart Failure Is Becoming a Cardiometabolic Disease
The 2026 ESC guideline changes how clinicians classify and treat heart failure. It removes the intermediate HFmrEF category, expands reduced-ejection-fraction heart failure below 50%, and recommends SGLT2 inhibitors and appropriate mineralocorticoid-receptor antagonists across the symptomatic spectrum. The guideline also brings obesity treatment, blood-pressure control, kidney protection, sleep evaluation, exercise, and muscle preservation into one integrated cardiometabolic framework for modern, individualized heart-failure care across diverse patients.
Published
Androgen Excess in Women: A Smarter Clinical Framework
Androgen excess in women often reflects more than a single hormonal imbalance. This blog explores a structured, thoughtful approach to evaluating elevated androgens, from common causes like PCOS to rarer endocrine conditions. By focusing on clinical patterns, metabolic context, and targeted testing, patients and clinicians can better understand symptoms and move toward meaningful, individualized care.
Published
2026 Dyslipidemia Guideline: What Changed, What Matters, and How I Apply It
The 2026 dyslipidemia guideline reshapes how we approach cholesterol and cardiovascular risk. It introduces the PREVENT risk model, restores LDL targets, and emphasizes earlier and more personalized treatment. Beyond LDL, the guideline highlights lipoprotein(a), apoB, and coronary calcium scoring. This broader, more integrated framework allows for smarter prevention and more precise long-term cardiovascular risk reduction.
Published
Primary Aldosteronism Guidelines: What the 2025 Update Changes
Primary aldosteronism is the most common endocrine cause of secondary hypertension, yet it remains widely underdiagnosed. Updated Endocrine Society guidelines highlight earlier screening, targeted aldosterone therapy, and the importance of renin guided treatment. These changes help reduce stroke, heart failure, and atrial fibrillation risk beyond blood pressure control alone.
Published
Key 2026 ADA Guideline Updates That Matter Most for Modern Diabetes Care
The 2026 ADA Standards of Care reflect a shift toward personalized, integrated diabetes management. These updates emphasize shared decision-making, earlier CGM use, weight-focused therapies, and cardiometabolic risk reduction. This summary explains what changed, why it matters, and how modern diabetes care now aligns glucose, weight, heart, kidney, and liver health.
Published
Categorized as Clinical Guidelines, Diabetes Care, Insights from Dr. Tashko, Insulin Resistance, Prediabetes Care
2024 NLA Expert Clinical Consensus on Apoprotein B (Apo B)
Here I summarize the National Lipid Association’s recent expert consensus, which emphasizes apolipoprotein B (Apo B) as a key tool in managing cardiovascular risk. Apo B, present on atherogenic lipoproteins, gives a more precise assessment of cardiovascular risk than traditional LDL cholesterol (LDL-C) measurements.
Published
Diabetes & Cardiovascular Disease
Atherosclerotic cardiovascular disease (ASCVD) is the leading cause of death among patients with diabetes. Therefore, managing ASCVD risk is crucial in preventing the progression of atherosclerosis and reducing serious events like heart attacks and strokes in individuals with diabetes.
Published
Categorized as ADA, Clinical Guidelines, Diabetes Care, Heart Health, Insights from Dr. Tashko, Lipid Health
Hypertension and Diabetes
Diabetes specialists and hypertension specialists should integrate the 2020 American Diabetes Association guidelines into their clinical practice. These guidelines emphasize achieving specific blood pressure targets for different patient groups. For instance, adults at high risk of ASCVD should aim for BP levels below 130/80 mmHg, while those with gestational diabetes should target below 135/85 mmHg. Individuals with low ASCVD risk should aim for BP levels below 140/90 mmHg. Lifestyle modifications and appropriate medications are key…
Published
Categorized as ADA, Blog, Clinical Guidelines, Diabetes Care, Hypertension, Insights from Dr. Tashko
Testosterone Supplementation
American College of Physician (ACP) committee conducted a systematic review of 38 randomized controlled clinical trials focusing on testosterone supplementation in individuals with age-related hypogonadism. The study participants had an average age of 66 years and baseline total testosterone measures ≤300 ng/dL. After careful analysis, the authors of the review reached a consensus and provided the following recommendations: Dr. Tashko Background A gradual, age-associated decline in serum total testosterone levels begins in men in their…
Published
Categorized as Age-Related Health Issues, Blog, Clinical Guidelines, Insights from Dr. Tashko, Testosterone
Medications for Type 2 Diabetes
It is important to note that the drug recommendations provided here are general and serve only as a guideline. The ultimate clinical decision should consider factors such as medication tolerability, cost, clinical context, glucose control, the patient’s weight loss goals, comorbidities, and patient preferences.
Published
Categorized as ADA, Blog, Clinical Guidelines, Diabetes Care, Drug Information, Insights from Dr. Tashko
Clinical Trials on Diabetes Safety
In 2008, the Food and Drug Administration mandated the pharmaceutical industry to prove cardiovascular safety for all new anti-diabetes medications. As a consequence, we presently have critically useful safety data from clinical trials like LEADER, SUSTAIN, CANVAS, PIONEER 6, DECLARE-TIMI 58, and REWIND.
Published
Key Revisions of 2020 ADA Guidelines
Here you can find the critical modifications in the 2020 ADA guidelines. Particular emphasis is placed on pharmacological therapy with GLP-1 agonists or SGLT-2 inhibitors for patients with established cardiovascular disease, heart failure, or chronic kidney disease. Guidelines are published yearly in January.
Published